Dr. Sami Ibrahimi, MD

Dr. Ibrahimi practices at Ou Medical Center-The Children's Ho - Rad CT - HOPD in Oklahoma City, Oklahoma.

Dr. Ibrahimi's NPI, 1295081511, was assigned on July 24, 2012. Dr. Ibrahimi graduated from University of Jordan Faculty of Medicine in 2010. Dr. Ibrahimi holds Oklahoma license 31318.

Dr. Ibrahimi's primary practice is Ou Medical Center-the Children's Ho - Rad CT - HOPD, at 1200 Childrens Ave, Oklahoma City, OK 73104.

Dr. Ibrahimi's primary practice is Ou Medical Center-The Children's Ho - Rad CT - HOPD in Oklahoma City, Oklahoma. Dr. Ibrahimi is also affiliated with OU Health University of Oklahoma Medical Center. The medical group on file is OU Health. Dmand AI also links Dr. Ibrahimi to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ibrahimi practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ibrahimi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Ibrahimi is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Ibrahimi's licenses on file in 2 states: Oklahoma and Massachusetts.

Dmand AI lists chronic leukemia, fluid and electrolyte imbalances, immune deficiency disease, lymphoma, multiple myeloma and purpura and thrombocytopenia among the conditions Dr. Ibrahimi treats.

CMS data shows 563 Medicare services from Dr. Ibrahimi across 6 procedure codes in 2024, for 168 Medicare patients. Medicare paid $39,863 for them.

CMS counts 168 Medicare patients who saw Dr. Ibrahimi in 2024. The largest group is 65 to 74, with 84 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.43, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ibrahimi's median patient age at 72, with 51% women.

In 2024, Dr. Ibrahimi wrote 230 Medicare Part D claims for 53 patients. 50% of them were for generic drugs. CMS names the drug for 90 of them, across 5 drugs with 11 or more claims each, at $870,572 in total drug cost. In 2023, CMS named 162 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 77 out of 100 for Dr. Ibrahimi for performance year 2024, reported as part of a group. Dr. Ibrahimi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 29 papers to Dr. Ibrahimi, published from 2017 to 2025. 2018 was the busiest year, with 5. The most frequent topics are Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols and Hematopoietic Stem Cell Transplantation. Dr. Ibrahimi has published most often in Clin Lymphoma Myeloma Leuk. Dr. Ibrahimi's most frequent co-authors are Sarbajit Mukherjee, Taha Mahdi Salih Al-Juhaishi, MD and Adam Asch, MD.

Dmand AI links Dr. Ibrahimi to 8 clinical trials, 2 of them phase 1/2 studies. 4 are still active or recruiting. Conditions studied include Lymphoma, Large B-Cell, Diffuse, Purpura, Thrombotic Thrombocytopenic and Lymphoma, Non-Hodgkin. National Cancer Institute (NCI) sponsors the most, 5. Open Payments lists research payments to Dr. Ibrahimi that name 1 trial.

CMS Open Payments shows 75 general payments to Dr. Ibrahimi from 26 drug and device companies from 2016 to 2025. Honoraria make up the largest share, 44% of the total. ADC Therapeutics America, Inc. paid the most, $13,458. It also lists 8 research payments totaling $1,160 in 2019, naming 1 clinical trial.

Dr. Ibrahimi graduated from University of Jordan Faculty of Medicine in 2010.

Dr. Ibrahimi is in network with 6 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 5. Check the plan with the practice before a visit.